Table 1.

Survey results in all respondents

Total Respondents	N=642
The FNR of SLND is:	638 Responses
<5%	42 (7%)
5–9%	155 (24%)
10–15%	336 (53%)
>15%	25 (4%)
Not familiar with the trial results	80 (13%)
Use of SLND alone before publication of trials:	636 Responses
Most of the time	110 (17%)
In select patients	175 (28%)
No	351 (55%)
Currently offer SLND with possible omission of ALND:	638 Responses
In the majority (>50%)	342 (54%)
In select patients (<50%)	201 (32%)
Perform ALND in all patients	95 (15%)
Features considered in determining if eligible for SLND:	560 Responses
Tumor size	116 (21%)
Number of abnormal axillary nodes on ultrasound at diagnosis	349 (62%)
Status of nodes on ultrasound after completing chemotherapy	346 (62%)
Tumor subtype	200 (36%)
Patient age	235 (42%)
Planned postoperative radiation	354 (63%)
Do not consider any of these	43 (8%)
Technical aspects considered critical for SLND:	Yes	No	No Response
Dual tracer	481 (86%)	77 (14%)	84
Removal of ≥ 2 SLN	332 (70%)	139 (30%)	171
Removal of ≥3 SLN	292 (61%)	184 (39%)	166
Placing clip to mark biopsied node and ensured removal	435 (82%)	97 (18%)	110
Immunohistochemistry	247 (50%)	247 (50%)	148
Normalization of nodes on ultrasound	247 (49%)	258 (51%)	137
Routinely place clips to mark biopsied nodes:	559 Responses
Yes	373 (67%)
No	186 (33%)
Intra-operative handling when clips are placed:	386 Responses
Wire localization	202 (52%)
Seed localization	36 (9%)
Other localization technique	38 (10%)
X-ray to confirm removal but no localization	90 (23%)
No assessment for clipped node	20 (5%)
Reasons SLND is not used:	212 Responses
Concerns about false negative rate	44 (21%)
Lack of oncologic outcome data	112 (53%)
Do not have the institutional resources required	64 (30%)
Resistance from medical oncologists	56 (26%)
Resistance from radiation oncologists	50 (24%)
Resistance from other surgeons	32 (15%)
Institution is collecting data	15 (7%)